← FDA DRUG APPROVALS

FDA ANDA · ANDA206674

BUPROPION HYDROCHLORIDE (SR)

bupropion hydrochloride

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA206674
TYPE
ANDA
ORIGINAL APPROVAL
2016-02-09
LATEST ACTION
2021-01-04
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

BUPROPION HYDROCHLORIDEDiscontinued
BUPROPION HYDROCHLORIDE 200MG · TABLET, EXTENDED RELEASE · ORAL
BUPROPION HYDROCHLORIDEDiscontinued
BUPROPION HYDROCHLORIDE 100MG · TABLET, EXTENDED RELEASE · ORAL
BUPROPION HYDROCHLORIDEDiscontinued
BUPROPION HYDROCHLORIDE 150MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2021-01-04Labeling · Supplement 10 · standardAP
2021-01-04Labeling · Supplement 5 · standardAP
2021-01-04Labeling · Supplement 13 · standardAP
2017-04-17Labeling · Supplement 1 · standardAP
2016-02-09UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →